300 related articles for article (PubMed ID: 35720644)
1. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab Vedotin in urothelial cancer.
Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
[TBL] [Abstract][Full Text] [Related]
3. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
McGregor BA; Sonpavde G
Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
[No Abstract] [Full Text] [Related]
4. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
5. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
6. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
8. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
[TBL] [Abstract][Full Text] [Related]
9. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
10. Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies.
Evmorfopoulos K; Mitrakas L; Karathanasis A; Zachos I; Tzortzis V; Vlachostergios PJ
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509415
[TBL] [Abstract][Full Text] [Related]
11. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.
Mollica V; Rizzo A; Montironi R; Cheng L; Giunchi F; Schiavina R; Santoni M; Fiorentino M; Lopez-Beltran A; Brunocilla E; Brandi G; Massari F
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32498352
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
Koshkin VS; Osbourne AS; Grivas P
Transl Androl Urol; 2021 Oct; 10(10):4022-4035. PubMed ID: 34804845
[TBL] [Abstract][Full Text] [Related]
13. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
Jain RK; Skelton WP; Zhang J
Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
15. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
Park I; Lee JL
Korean J Intern Med; 2020 Jul; 35(4):834-853. PubMed ID: 32668516
[TBL] [Abstract][Full Text] [Related]
18. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
19. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Grimm MO; Foller S; Leeder M; Leucht K
Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
Tripathi A; MacDougall K; Sonpavde GP
Drugs; 2022 Nov; 82(17):1649-1662. PubMed ID: 36441503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]